Progress in targeted therapy for breast cancer

Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jie Ju, An-Jie Zhu, Peng Yuan
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9a5f812652b04672861ee0071144abcf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a5f812652b04672861ee0071144abcf
record_format	dspace
spelling	oai:doaj.org-article:9a5f812652b04672861ee0071144abcf2021-12-02T13:21:23ZProgress in targeted therapy for breast cancer2095-882X10.1016/j.cdtm.2018.04.002https://doaj.org/article/9a5f812652b04672861ee0071144abcf2018-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300069https://doaj.org/toc/2095-882XBreast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems. Keywords: Breast cancer, Targeted therapy, Precision medicineJie JuAn-Jie ZhuPeng YuanKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 3, Pp 164-175 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jie Ju An-Jie Zhu Peng Yuan Progress in targeted therapy for breast cancer
description	Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems. Keywords: Breast cancer, Targeted therapy, Precision medicine
format	article
author	Jie Ju An-Jie Zhu Peng Yuan
author_facet	Jie Ju An-Jie Zhu Peng Yuan
author_sort	Jie Ju
title	Progress in targeted therapy for breast cancer
title_short	Progress in targeted therapy for breast cancer
title_full	Progress in targeted therapy for breast cancer
title_fullStr	Progress in targeted therapy for breast cancer
title_full_unstemmed	Progress in targeted therapy for breast cancer
title_sort	progress in targeted therapy for breast cancer
publisher	KeAi Communications Co., Ltd.
publishDate	2018
url	https://doaj.org/article/9a5f812652b04672861ee0071144abcf
work_keys_str_mv	AT jieju progressintargetedtherapyforbreastcancer AT anjiezhu progressintargetedtherapyforbreastcancer AT pengyuan progressintargetedtherapyforbreastcancer
_version_	1718393227177885696

Progress in targeted therapy for breast cancer

Ejemplares similares